Table 1

Characteristics by group

Normal cognitive performance (n=22)Cognitively impaired (n=40)
Mean (SD)Mean (SD)Mean difference (95% CI)p Value
Age (years)51.27 (9.70)48.30 (8.33)2.97 (−1.72 to 7.66)0.210
Disease duration (years)10.77 (7.30)12.65 (8.21)2.10 (−6.07 to 2.32)0.375
Expanded Disability Status Scale3.48 (1.74)4.34 (1.70)−0.86 (−1.77 to 0.05)0.065
Education (years)14.05 (2.34)13.80 (2.78)0.25 (−1.15 to 1.64)0.614
N/22 (%)N/40 (%)OR (95% CI)p Value
Gender (female)15 (68.2)28 (70)1.09 (0.35 to 3.35)0.882
Unemployed7 (31.8)28 (70)5.00 (1.63 to 15.38)0.009
Disease subtype
 Relapsing-remitting17 (77.3)27 (67.5)0.61 (0.19 to 2.02)0.417
 Secondary-progressive5 (22.7)13 (32.5)
On treatment at enrolment to study12 (54.5)19 (47.5)0.75 (0.266 to 2.14)0.596
 Interferon*36
 Glatiramer acetate20
 Fingolimod65
 Natalizumab07
 Teriflunomide11
  • *Includes interferon(IF)-1b subcutaneous, IF-1A intramuscular and IF-1A subcutaneous.